Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development and validation of a prognostic model for adult patients with acute myeloid leukaemia.

EBioMedicine - 1 Dec 2020

Ma Ting-Ting, Lin Xiao-Jing, Cheng Wen-Yan, Xue Qing, Wang Shi-Yang, Liu Fu-Jia, Yan Han, Zhu Yong-Mei, Shen Yang

Abstract excerpt

BACKGROUND: The high heterogeneity of acute myeloid leukaemia (AML) reflected in the patient- and disease-related factors accounts for the unsatisfactory prognosis despite the introduction of novel therapeutic approaches and drugs in recent years. METHODS: In the development set (n = 412), parameters including age, hematopoietic cell transplantation-comorbidity index, white blood cell count, hemoglobin, biallelic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Clinical Decision-Making

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Management

Share to Disease Susceptibility

Share to Leukemia, Myeloid, Acute

Share to Models, Theoretical

Share to Nucleophosmin

Share to ROC Curve

Source

Open in PubMed Open full text

Identifiers

PMID: 33232873
DOI: 10.1016/j.ebiom.2020.103126
PMCID: PMC7689519

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development and validation of a prognostic model for adult patients with acute myeloid leukaemia.PMID 33232873Read ↗

Prognostic nomogram for previously untreated adult patients with acute myeloid leukemia.Semantic proximity Read ↗

A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries.Semantic proximity Read ↗

AML Risk Stratification Models Utilizing ELN-2017 Guidelines and Additional Prognostic Factors: A SWOG ReportSemantic proximity Read ↗

Prognosis and treatment in acute myeloid leukemia: a comprehensive reviewSemantic proximity Read ↗

Prognostic factors for acute myeloid leukaemia in adults - biological significance and clinical useSemantic proximity Read ↗

Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia.Semantic proximity Read ↗

Multiple machine-learning tools identifying prognostic biomarkers for acute Myeloid LeukemiaSemantic proximity Read ↗

The characteristics and prognostic analysis of therapy-related acute myeloid leukemia patients in China.Semantic proximity Read ↗

A dynamic 3-factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy.Semantic proximity Read ↗

Precision survival estimation in acute myeloid leukemia using evolutionary learning-derived microRNA signatureSemantic proximity Read ↗

Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia.Semantic proximity Read ↗

Development and validation of a prognostic scoring model to risk stratify childhood acute myeloid leukaemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.